Speaker illustration

Doctor Peter Noseworthy

Mayo Clinic, Rochester (United States of America)

Peter Noseworthy, MD is a Professor of Medicine and a Cardiac Electrophysiologist specializing in catheter ablation of cardiac arrhythmias. He completed his Medicine, Cardiology, Chief residency and electrophysiology training at Massachusetts General Hospital and joined the Mayo Clinic faculty in 2013. Dr. Noseworthy maintains a federally funded research program centered on improving the care of patients with cardiac arrhythmias. He has a concurrent role in the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery where he works leading several prospective pragmatic RCTs and is leading various analyses of national datasets. He serves as the director of the Mayo Clinic Heart Rhythm and Physiologic Monitoring Laboratory where he leads a multidisciplinary team working to develop novel ECG software-based analysis tools.

Digital health is the new paradigm - in practice: learn from the masters

Event: EHRA 2023

Topic: Big Data and Digital Twin

Session: Modern arrhythmia care from the digital perspective

Thumbnail

Machine learning in AF detection - the problem/the issue: how can ML be of use in predicting incidental atrial fibrillation

Event: EHRA 2023

Topic: Diagnostic Methods

Session: Novel tools for AF detection

Thumbnail

Future directions: artificial intelligence for early detection of AF.

Event: EHRA 2022

Topic: e-Cardiology/Digital Health

Session: To screen or not to screen for atrial fibrillation (AF)

Thumbnail

The effect of shared decision-making for stroke prevention on treatment adherence and safety outcomes in patients with atrial fibrillation: a randomized clinical trial

Event: ESC Congress 2021 - The Digital Experience

Topic: Stroke Prevention

Session: Atrial fibrillation e-posters

Thumbnail

Age and gender differences in stroke and bleeding risks in atrial fibrillation patients treated with non-vitamin K antagonist oral anticoagulants

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation

Thumbnail

Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Anticoagulation in atrial fibrillation

Thumbnail

Utilization and effectiveness of alirocumab and evolocumab in improving lipid profile in routine clinical practice

Event: ESC Congress 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Lipids

Thumbnail

The impact of age on the effectiveness and safety of the NOACs versus warfarin for stroke prevention in atrial fibrillation

Event: ESC Congress 2017

Topic: Atrial fibrillation (AF)

Session: Progress in stroke prevention in atrial fibrillation

Thumbnail

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb